Skip to main content

Oncology Central is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • News
  • Events coverage
  • Features
    • Opinion
    • Journal articles
    • Events calendar
    • Spotlights
    • In Focus

    Follow us on social media

  • Our Journals
  • Topic
    • Prevention, detection and screening
      • Biomarkers
      • Diagnostics
      • Epidemiology
      • Genetics & genomics
      • Prevention & screening
    • Bench to bedside
      • Cancer biology
      • Clinical trials
      • Drug approvals
      • Drug development
      • Emerging technologies
      • Industry & business
      • Preclinical research
    • Treatments
      • Chemotherapy
      • Immuno-oncology
      • Personalized & precision medicine
      • Radiology
      • Surgery
      • Targeted therapies
    • Supportive oncology
      • Palliative care
      • Patient perspectives
      • Quality of life
      • Survivorship
      • Virtual healthcare

    Follow us on social media

  • Disease specialty
    • Breast
    • Colorectal
    • Endocrine
    • Gastrointestinal
    • Genitourinary
    • Gynecologic
    • Head & neck
    • Hematologic
    • Hepatic
    • Lung
    • Neurologic
    • Pancreatic
    • Prostate
    • Rare tumors
    • Renal
    • Skin

    Follow us on social media

  • Multimedia
    • Videos
    • Podcasts
    • Infographics
    • Webinars
    • Downloadable eBooks

    Follow us on social media

  • Register
[COFFEE CHAT] The emotional and psychological impact of hepatocellular carcinoma on patients, families and caregivers WATCH NOW

Spotlight on cancer and the immune system

Cancer immunotherapy is arguably one of the biggest developments and one of hottest topic within oncology. This Spotlight reviews the intricacies of how cancer cells and immune cells interact, look at the escape mechanisms that cancers employ to evade an antitumor immune response and explore the story behind some of the novel immunotherapy agents that have been developed to reverse this immune evasion.

Articles

Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice
KEYNOTE-048: pembrolizumab changes the rules for head and neck cancer patients
T-VEC: what’s next for oncolytic virotherapy and immuno-oncology?
Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice
Deciding when to stop immunotherapy: exploring KEYNOTE-006 data
The Patient Perspective on… immunotherapy advancements
Checkpoint inhibitors for renal cell carcinoma: current landscape and future directions
Seven challenges in immuno-oncology
Are there, or shall we discover, biomarkers to guide PD-1 inhibition?
Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies
  • About
  • Accessibility
  • Advertising & Sponsorship
  • Contact Us
  • Editorial Policies
  • Expert Panel
  • Journals
  • Permissions and content ownership policy
  • Press release policy
  • Whitelist emails

Contact

Contact Us

Office info

Oncology Central is powered by Taylor & Francis Group

Oncology Central, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2026 Oncology Central